The GRPR Antagonist [(99m)Tc]Tc-maSSS-PEG(2)-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity

Gastrin-releasing peptide receptors (GRPRs) are overexpressed in the majority of primary prostate tumors and in prostatic lymph node and bone metastases. Several GRPR antagonists were developed for SPECT and PET imaging of prostate cancer. We previously reported a preclinical evaluation of the GRPR...

Descripción completa

Detalles Bibliográficos
Autores principales: Abouzayed, Ayman, Borin, Jesper, Lundmark, Fanny, Rybina, Anastasiya, Hober, Sophia, Zelchan, Roman, Tolmachev, Vladimir, Chernov, Vladimir, Orlova, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178091/
https://www.ncbi.nlm.nih.gov/pubmed/37175001
http://dx.doi.org/10.3390/diagnostics13091611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178091/
https://www.ncbi.nlm.nih.gov/pubmed/37175001
http://dx.doi.org/10.3390/diagnostics13091611

Ejemplares similares